title: [What is new in pediatric oncology?].
abstract: The significant progress made in pediatric oncology during recent years has been due to a major breakthrough in the field of molecular biology and the introduction of new therapeutic strategies that take into account both the quality and the duration of life. Molecular biology has already been instrumental in more fully categorizing the 'small round-cell tumor' group, and in reclassifying the 'Ewing family' tumors. It also provides a valuable tool for the prognostic evaluation of neuroblastomas through the analysis of the N-myc oncogene. In addition, it has permitted the identification of the Li-Fraumeni syndrome of predisposition to cancer in the child, thereby raising the problematical ethical issue of communicating relevant information to subjects at risk. Two examples illustrate innovative strategic concepts: 1) Burkitt's lymphoma, or an example of the successful de-intensification of treatment; and 2) brain tumors in young children, regarding which the desire to improve the quality of life has led to innovative attempts to replace radiotherapy by chemotherapy. Considerable progress has been made in the field of neuropsychology, thereby permitting an improved assessment of disorders and a better management of rehabilitation programs. New anti-cancer agents and also chemo- and radiotherapy that spare healthy tissue are also being developed. Gene therapy and molecular biology will play a major role in future therapeutic strategies; and are now at the preclinical trial stage. This significant overall progress leads to a reconsideration of the organizational approach toward treatment of the pediatric patient population suffering from cancer, and a critical assessment of disease management, which should take into account not only the technical aspects of the disease but also familial and social considerations.
authors.affiliation: Service de pédiatrie, institut Gustave-Roussy, Villejuif, France.
authors.forename: O
authors.initials: O
authors.lastname: Oberlin
authors.forename: L
authors.initials: L
authors.lastname: Brugières
authors.forename: C
authors.initials: C
authors.lastname: Patte
authors.forename: C
authors.initials: C
authors.lastname: Kalifa
authors.forename: G
authors.initials: G
authors.lastname: Vassal
authors.forename: D
authors.initials: D
authors.lastname: Valteau-Couanet
authors.forename: O
authors.initials: O
authors.lastname: Hartmann
mesh_terms: D001932:Brain Neoplasms / Q000628:therapy; D002051:Burkitt Lymphoma / Q000188:drug therapy; D002648:Child; D020022:Genetic Predisposition to Disease; D006801:Humans; D008495:Medical Oncology / Q000639:trends*; D009857:Oncogenes; D010372:Pediatrics / Q000639:trends*; D011788:Quality of Life